Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Protai logo — Proteomics & AI Drug discovery

Protai

Proteomics & AI Drug discovery

Founded 2021 Israel Israel 29 employees Seed Total: $20.00M AI, Biotechnology +1

General Information

Company Name Protai
Founded Year 2021
Location Israel Israel
Employees 29
Industries AI, Biotechnology, Life Sciences
Funding Stage Seed
Business Model Platform, B2B, SaaS
Revenue Model Licensing, Project Based, Subscription
Social

BounceWatch is an independent company data service, not affiliated with Protai. To contact Protai, visit protai.bio.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Protai compare?

A PDF of Protai and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Protai soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Protai

Protai, founded in 2021 and headquartered in Israel, leverages cutting-edge technologies in AI, Biotechnology, and Life Sciences to revolutionize drug discovery. By utilizing an AI-based platform, Protai delves into the proteomic landscape to map diseases at the protein level, offering a novel approach to observing cellular functions and streamlining the drug discovery process.

The company recently secured a $12.00 million seed investment on 01 March 2023, attracting the attention of notable investors such as Grove Ventures, Maj Invest Private Equity, and Pitango Venture Capital. This capital injection underscores investor confidence in Protai's potential to impact the biomedical sector.

As the intersection of AI and proteomics continues to transform drug discovery, Protai stands out by offering a robust platform that promises to expedite and enhance the development of new therapeutics. For investors eyeing innovation in healthcare, Protai represents a promising venture with the potential to yield significant scientific and economic returns.

Business keywords: Proteomics, AI Drug Discovery, End-to-End AI Platform, Cellular Function Analysis, Biological Insights, Complex Disease Combat, Protein Level Mapping, Drug Candidate Creation, Drug Discovery Facilitation, Advanced Drug Discovery, Disease Mapping, Molecular Biology, Pharmaceutical Innovation, Biotech

Services & Products

Structural Proteomics Integration
AI-Driven Drug Discovery
Pipeline Development
End-to-End Drug Discovery Collaboration
AIMS™ Platform Utilization

Target Customers

Pharmaceutical Companies Biotech Firms Research Institutions Healthcare Innovators Partnering Enterprises

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed $12.00M 3
Grove Ventures Maj Invest Private Equity Pitango Venture Capital
Grove Ventures, Maj Invest Private Equity +1
01 Mar 2023
Seed $8.00M 2
Grove Ventures Pitango Venture Capital
Grove Ventures, Pitango Venture Capital
01 Jan 2022

Protai Alternatives & Competitors

View All Alternatives
Protai vs
PROTEINA
PROTEINA Korea South

Our Protein-protein interaction (PPI) analysis platform enables quantitative measurements at the sin...

Series C
32 employees
Biotechnology, Health Care
Compare Protai vs PROTEINA
Protai vs
SARomics Biostructures AB
SARomics Biostructures AB Sweden

Protein Crystallography & Integrated Drug Discovery: Fragment Screening & Fragment-Based Drug Design...

Venture round
31 employees
Biotechnology, Health Care
Compare Protai vs SARomics Biostructures AB
Protai vs
Quantum-Si
Quantum-Si United States

The Protein Sequencing Company™

IPO
186 employees
Biotechnology, Health Care
View all alternatives

FAQ About Protai

Proteomics & AI Drug discovery
Protai was founded in 2021.
Protai is headquartered in Israel.
Protai operates in AI, Biotechnology and Life Sciences. Its work centres on Proteomics, AI Drug Discovery, End-to-End AI Platform and Cellular Function Analysis. Its customers include Pharmaceutical Companies, Biotech Firms and Research Institutions.
Protai has a Platform, B2B and SaaS business model. Its revenue comes from Licensing, Project Based and Subscription.
Protai has approximately 29 employees.
Protai has completed 2 funding rounds, raising a total of $20.00M. The latest funding stage is Seed.
Protai offers: Structural Proteomics Integration, AI-Driven Drug Discovery, Pipeline Development, End-to-End Drug Discovery Collaboration, AIMS™ Platform Utilization.
Top alternatives and competitors to Protai include PROTEINA, SARomics Biostructures AB, Quantum-Si, Turbine, 1910 Genetics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Protai and PROTEINA are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Protai, https://bouncewatch.com/company/protai, updated 15 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes